New hope for liver cancer patients when first-line therapy fails
NCT ID NCT07537777
First seen Apr 23, 2026 · Last updated Jun 08, 2026 · Updated 9 times
Summary
This study tests a combination of two drugs (benmelstobart and anlotinib) plus targeted radiation for people with liver cancer that has spread to a few spots and stopped responding to initial treatment. About 29 adults will receive this therapy in 3-week cycles to see if it can control the cancer longer. The goal is to measure how long the cancer stays stable, tumor shrinkage, and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.